Semaglutide vs. Ozempic vs. Wegovy: Why the Same Molecule Has Three Names

Semaglutide is the active drug; Ozempic and Wegovy are brand names for products containing that same molecule, made by the same manufacturer, Novo Nordisk. The confusion around them isn't about different drugs — it's about how one molecule became two separately regulated, separately marketed products.

Same Molecule, Different FDA Approvals

Ozempic was approved first, in 2017, specifically for type 2 diabetes management, and its FDA-approved labeling and marketing are built around blood sugar control, with weight loss listed as a secondary effect rather than the primary indication. Wegovy is the same semaglutide molecule, approved separately in 2021, specifically for chronic weight management in people with obesity or overweight with a weight-related condition, at doses developed and tested for that indication. The FDA requires separate approval processes and separate labeling for each indication, which is why the same drug ends up marketed under two names rather than one.

The Dose Difference That Actually Matters

Wegovy's maximum approved dose (2.4mg weekly) is higher than Ozempic's maximum approved dose (2mg weekly) — a real pharmacological difference, not just branding, reflecting that the weight-management indication was studied and approved at a higher target dose than the diabetes indication used in Ozempic's own trials.

Why Insurance Treats Them So Differently

Because Ozempic is FDA-approved for diabetes and Wegovy for weight management, insurance coverage frequently follows the approved indication rather than the underlying molecule — many plans cover Ozempic more readily for a diabetes diagnosis while requiring extensive prior authorization, or denying coverage outright, for Wegovy's weight-management indication. This has driven a well-documented pattern of off-label Ozempic prescribing for weight loss in patients without diabetes, seeking to access semaglutide through the better-covered pathway — a practice that sits in a gray area relative to the drug's actual approved use.

Rybelsus: The Third Semaglutide Product

Rybelsus is an oral semaglutide tablet, also approved for type 2 diabetes, using a different delivery mechanism (absorption enhancer technology to survive the digestive tract) than the injectable Ozempic/Wegovy pens — a third semaglutide product with its own approval, dosing schedule, and administration method entirely distinct from the injectables.

Practical Takeaway

Ozempic, Wegovy, and Rybelsus are all semaglutide, but they aren't interchangeable in a practical or regulatory sense — different approved indications, different maximum doses, different delivery methods for Rybelsus specifically, and very different insurance coverage pathways. Understanding which product name maps to which approved use explains most of the confusion (and off-label prescribing patterns) around this drug in ways that just knowing 'they're the same molecule' doesn't fully clarify.